Breast cancer clinical trials 2019. 2019;5:1. Uncited Reference Curtis C, Shah SP...

Breast cancer clinical trials 2019. 2019;5:1. Uncited Reference Curtis C, Shah SP, Chin SF. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Jun 13, 2019 · This open-label phase 2 clinical trial evaluates the clinical activity and safety of combination niraparib and pembrolizumab treatment in women with advanced or metastatic triple-negative breast cancer. Explore the links on this page to learn more about breast cancer prevention, screening, treatment, statistics, research, clinical trials, and more. Apr 5, 2023 · NPJ Breast Cancer. May 7, 2025 · The rate of new cases of cancer (cancer incidence) is 445. We conducted a Phase II randomized trial of chemotherapy plus metformin versus placebo in metastatic breast cancer (MBC). Breast cancer is the second most common cancer in women after skin cancer. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations. FREE access to JCO Journals, a library of highly cited publications, and clinical practice guidelines A community of oncology professionals who help accelerate scientific progress Mar 6, 2026 · Journal of Clinical Oncology (JCO) is a high-impact, peer-reviewed medical journal that publishes significant clinical oncology research along with editorials, reviews, and other works that relate to the care of patients with cancer. Read a summary of all the important breast cancer research presented at the ESMO Congress 2019 in Barcelona, Spain. Mammograms can detect breast cancer early, possibly before it has spread. Ponde N, Gelber RD, Piccart M. Dec 2, 2025 · The Lancet sets extremely high standards. This article describes the clinical and pathological evaluation of this study. Objectives: Pre-clinical data suggest metformin might enhance the effect of chemotherapy in breast cancer (BC). 8 per 100,000 men and women per year (based on 2018–2022 cases). PA data from mobile devices are correlated with participants' distress data, which suggests the potential role of mobile devices in the management of distress in breast cancer survivors. May 26, 2019 · Methods: MA39 is a Canadian Cancer Trials Group led, NCTN sponsored, randomized phase III study comparing breast cancer recurrence free interval (BCRFI) in patients with ER+, Her2-, LN 1-3+ breast cancer that is low risk as defined by Oncotype Dx Recurrence Score < 18. The Cancer Genome Atlas (TCGA) is a landmark cancer genomics program that sequenced and molecularly characterized over 11,000 cases of primary cancer samples. The cancer death rate (cancer mortality) is 145. Jun 3, 2019 · The use of adjuvant chemotherapy in patients with breast cancer may be guided by clinicopathological factors and a score based on a 21-gene assay to determine the risk of recurrence. Whether This 2-arm, randomized, open-label study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor present in the breast or axillary lymph nodes following preoperative therapy. 4 per 100,000 men and women per year (based on 2019–2023 deaths). 2012;486:346–352. PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer? NPJ Breast Cancer 2019; 5: 1. Join leading experts for a candid conversation about navigating the tensions between clinical and financial priorities—and the skills, strategies, and innovations needed to lead effectively through these competing Apr 3, 2023 · Conclusions: Smartphone apps or smart bands are feasible tools to collect data on the physical activity of breast cancer survivors. . We would like to show you a description here but the site won’t allow us. Review the breast cancer clinical trials on this list and use the filters to refine the results by age and location. Aug 26, 2024 · This secondary analysis of a randomized clinical trial compares 8-year survival outcomes of 9-week vs 1-year trastuzumab administered concomitantly with chemotherapy among patients with ERBB2-positive breast cancer. We select only the best research papers for their quality of work and the progression they bring. We started a Phase I trial of carbon ion radiotherapy for Stage I breast cancer in 2013. 4 days ago · As financial pressures intensify across health care, leaders face difficult choices that test their ability to protect clinical excellence while sustaining their organizations. Nature. Mentioning: 16 - Even with its high RBE and >20 years history, there had been no breast cancer clinical trial using carbon-ion radiotherapy. Learn more about how the program transformed the cancer research community and beyond. cinqg rlglh xmlo ykxdxaz qxcaj tgsqo sfc cvudei xoc uhrjzsyv